Clinical Trials
75 trialsNeoB-Cap1
Novartis
OP-NEU-101
Onchilles Pharma Inc
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
SELECT-2CAR
Beijing Biotech
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Beijing Biotech
INX-315-01
Incyclix Bio
DUAL-NK-BC
Beijing Biotech
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PNeoVCA
Mayo Clinic
SELECT-CAR-NK
Essen Biotech
EBNK-ST-001
Essen Biotech
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
TAGNOT
Kidney Cancer Research Bureau
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Immune Cell Therapy for Advanced Solid Tumors
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Memorial Sloan Kettering Cancer Center
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
ABILITY-1
Medicenna Therapeutics, Inc.
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
M.D. Anderson Cancer Center
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
SYNERGY
Jules Bordet Institute
EDO-S101
Mundipharma Research Limited
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
COMPASS-TNBC
Gustave Roussy, Cancer Campus, Grand Paris
ORCHID-1
Medikine, Inc.
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
TILS001
Fundacio Clinic Barcelona
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
2019-101826
Providence Health & Services
PIVOT-02
Nektar Therapeutics
REVEAL
Nektar Therapeutics
REGOMUNE
Institut Bergonié
Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer
St. Olavs Hospital
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
A Study of AK-01 (LY3295668) in Solid Tumors
Eli Lilly and Company
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute